Quantitative analysis of contribution of mild and moderate hyperthermia to thermal ablation and sensitization of irreversible electroporation of pancreatic cancer cells.

Autor: Agnass P; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Surgery, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: p.agnass@amsterdamumc.nl., Rodermond HM; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: h.rodermond@amsterdamumc.nl., van Veldhuisen E; Amsterdam UMC Location University of Amsterdam, Surgery, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: e.vanveldhuisen@amsterdamumc.nl., Vogel JA; Amsterdam UMC Location University of Amsterdam, Gastroenterology & Hepatology, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: j.a.vogel@amsterdamumc.nl., Ten Cate R; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: rosemarie.cate@nijgeertgen.nl., van Lienden KP; Department of Intervention Radiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: k.van.lienden@antoniusziekenhuis.nl., van Gulik TM; Amsterdam UMC Location University of Amsterdam, Surgery, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: t.m.vangulik@amsterdamumc.nl., Franken NAP; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: n.a.franken@amsterdamumc.nl., Oei AL; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Oncology and Radiobiology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam UMC Location University of Amsterdam, Experimental Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: a.l.oei@amsterdamumc.nl., Kok HP; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, Amsterdam, the Netherlands. Electronic address: h.p.kok@amsterdamumc.nl., Besselink MG; Amsterdam UMC Location University of Amsterdam, Surgery, Meibergdreef 9, Amsterdam, the Netherlands. Electronic address: m.g.besselink@amsterdamumc.nl., Crezee J; Amsterdam UMC Location University of Amsterdam, Radiation Oncology, Meibergdreef 9, Amsterdam, the Netherlands; Cancer Center Amsterdam, Treatment and Quality of Life, Cancer Biology and Immunology, Amsterdam, the Netherlands. Electronic address: h.crezee@amsterdamumc.nl.
Jazyk: angličtina
Zdroj: Journal of thermal biology [J Therm Biol] 2023 Jul; Vol. 115, pp. 103619. Date of Electronic Publication: 2023 Jun 16.
DOI: 10.1016/j.jtherbio.2023.103619
Abstrakt: Introduction: Irreversible electroporation (IRE) is an ablation modality that applies short, high-voltage electric pulses to unresectable cancers. Although considered a non-thermal technique, temperatures do increase during IRE. This temperature rise sensitizes tumor cells for electroporation as well as inducing partial direct thermal ablation.
Aim: To evaluate the extent to which mild and moderate hyperthermia enhance electroporation effects, and to establish and validate in a pilot study cell viability models (CVM) as function of both electroporation parameters and temperature in a relevant pancreatic cancer cell line.
Methods: Several IRE-protocols were applied at different well-controlled temperature levels (37 °C ≤ T ≤ 46 °C) to evaluate temperature dependent cell viability at enhanced temperatures in comparison to cell viability at T = 37 °C. A realistic sigmoid CVM function was used based on thermal damage probability with Arrhenius Equation and cumulative equivalent minutes at 43 °C (CEM43°C) as arguments, and fitted to the experimental data using "Non-linear-least-squares"-analysis.
Results: Mild (40 °C) and moderate (46 °C) hyperthermic temperatures boosted cell ablation with up to 30% and 95%, respectively, mainly around the IRE threshold E th,50% electric-field strength that results in 50% cell viability. The CVM was successfully fitted to the experimental data.
Conclusion: Both mild- and moderate hyperthermia significantly boost the electroporation effect at electric-field strengths neighboring E th,50% . Inclusion of temperature in the newly developed CVM correctly predicted both temperature-dependent cell viability and thermal ablation for pancreatic cancer cells exposed to a relevant range of electric-field strengths/pulse parameters and mild moderate hyperthermic temperatures.
Competing Interests: Declaration of competing interest Author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: K.P.v.L. and T.M.v.G. are paid consultants for Angio-Dynamics. Angio-Dynamics had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
(Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE